Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Down 29.4% in December

Vivani Medical, Inc. (NASDAQ:VANI) saw a significant decline in short interest in December. As of December 15th, there was short interest totaling 220,276 shares, a decline of 29.4% from the November 30th total of 312,110 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 141,464 shares, the short-interest ratio is currently 1.6 days. Based on an average daily trading volume, of 141,464 shares, the short-interest ratio is currently 1.6 days. Currently, 0.6% of the shares of the stock are short sold.

Vivani Medical Stock Down 4.5%

Shares of VANI opened at $1.27 on Monday. The business has a fifty day moving average of $1.46 and a 200 day moving average of $1.38. The company has a market cap of $92.65 million, a PE ratio of -2.82 and a beta of 3.24. Vivani Medical has a 52-week low of $0.91 and a 52-week high of $1.92.

Vivani Medical (NASDAQ:VANI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. As a group, research analysts anticipate that Vivani Medical will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Gregg Williams purchased 3,703,703 shares of the business’s stock in a transaction on Monday, October 27th. The stock was acquired at an average price of $1.62 per share, for a total transaction of $5,999,998.86. Following the acquisition, the director directly owned 21,350,815 shares of the company’s stock, valued at $34,588,320.30. This represents a 20.99% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders purchased 8,916,996 shares of company stock worth $11,943,153 over the last three months. 46.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Vivani Medical

A number of hedge funds have recently added to or reduced their stakes in VANI. Panagora Asset Management Inc. bought a new stake in shares of Vivani Medical during the second quarter valued at approximately $25,000. Citadel Advisors LLC purchased a new position in Vivani Medical during the 3rd quarter worth $26,000. Finally, Susquehanna International Group LLP increased its holdings in Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after purchasing an additional 16,200 shares during the period. 6.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on VANI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Tuesday, October 14th. Zacks Research upgraded shares of Vivani Medical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 12th. Wall Street Zen raised shares of Vivani Medical to a “sell” rating in a research note on Saturday, November 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Vivani Medical in a report on Tuesday, September 2nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Vivani Medical presently has a consensus rating of “Hold” and an average price target of $4.00.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.